GHRP-6 and Ipamorelin have been studied as growth hormone secretagogues with broadly comparable GH-releasing activity in several experimental models, while showing differences in other endocrine responses. The most direct comparison comes from a 1998 pharmacology study that examined both compounds in primary rat pituitary cells, pentobarbital-anesthetized rats, and conscious swine. Researchers measured GH release alongside ACTH, cortisol, FSH, LH, prolactin and TSH. That study provides a direct basis for comparing the two compounds. It does not establish what happens when GHRP-6 and Ipamorelin are evaluated together. That distinction is important when interpreting the available research.
Why GHRP-6 and Ipamorelin Are Compared
GHRP-6 and Ipamorelin were directly compared during the early pharmacological characterization of Ipamorelin. The 1998 study examined GH release in primary rat pituitary cells and animal models while also measuring other endocrine responses.
The study found similar GH-releasing potency and efficacy in primary rat pituitary cells. Comparable GH responses were also reported in anesthetized rats and conscious swine. The endocrine measurements showed a different pattern for ACTH and cortisol, providing a basis for distinguishing the compounds beyond their GH response.
What the Direct Comparison Study Measured
The 1998 study examined several measurable endpoints rather than relying on GH release alone.
In primary rat pituitary cells, Ipamorelin produced an EC50 of 1.3 ± 0.4 nmol/L and an Emax of 85 ± 5%. GHRP-6 produced an EC50 of 2.2 ± 0.3 nmol/L and an Emax of 100%. The authors described the potency and efficacy of the two compounds as similar in this model.
In pentobarbital-anesthetized rats, Ipamorelin produced an ED50 of 80 ± 42 nmol/kg and an Emax of 1545 ± 250 ng GH/mL. GHRP-6 produced an ED50 of 115 ± 36 nmol/kg and an Emax of 1167 ± 120 ng GH/mL. The study therefore reported comparable GH-releasing activity in this model as well.
In conscious swine, the study measured an ED50 of 2.3 ± 0.03 nmol/kg and an Emax of 65 ± 0.2 ng GH/mL plasma for Ipamorelin. GHRP-6 produced an ED50 of 3.9 ± 1.4 nmol/kg and an Emax of 74 ± 7 ng GH/mL plasma. Again, the authors described the responses as very similar.
The experimental panel also included:
- ACTH
- cortisol
- FSH
- LH
- prolactin
- TSH
- responses to GHRP and GHRH antagonists
The antagonist experiments showed that Ipamorelin, like GHRP-6, stimulated GH release through a GHRP-like receptor.
Different Experimental Profiles Through a GHRP-Like Receptor
The direct comparison becomes more informative when the non-GH measurements are considered.
In conscious swine, GHRP-6 increased plasma ACTH and cortisol. Ipamorelin did not produce ACTH or cortisol levels significantly different from those observed after GHRH stimulation. The study reported that this difference remained evident at exposure levels more than 200-fold above the ED50 for GH release.
The same swine experiments found no significant effects from the tested GH secretagogues on FSH, LH, prolactin, or TSH. The results therefore showed that comparable GH responses did not correspond to identical endocrine profiles across the measured hormones.
A 2000 study provides another example of the compounds being investigated separately. Adult female rats received either Ipamorelin or GHRP-6 as individual treatments, with bone mineral content and related bone measurements assessed during the study. The compounds were not evaluated as a combined treatment.
What Changes When the Two Peptides Are Considered as a Combination
The research question changes when GHRP-6 and Ipamorelin are evaluated together.
The 1998 comparison established that both compounds produced GH responses and that both acted through a GHRP-like receptor system in the experimental pharmacology described. However, the compounds were evaluated separately. The study therefore does not establish whether combined exposure produces a different response from either compound alone.
The 2000 rat study does not resolve this question. GHRP-6 and Ipamorelin were assigned to separate treatment groups rather than evaluated together. Its findings therefore provide information about the individual treatments, not a combination-specific response.
Other research has examined combinations involving GHRP-6 and GHRH. In one study, combined GHRP-6 and GHRH produced a greater GH response than either stimulus alone. Earlier cell research also reported a synergistic effect between GHRP-6 and GHRH on GH release. These studies involved GHRH, however, not Ipamorelin, so they do not establish the response to a GHRP-6 and Ipamorelin combination.
What the Existing Research Can and Cannot Establish
The published studies establish several specific findings.
The research can establish:
- GHRP-6 and Ipamorelin produce GH responses in experimental models.
- Direct pharmacological comparison between the two compounds has been reported.
- Their GH responses were broadly comparable in the tested rat and swine models.
- Their endocrine profiles were not identical, particularly for ACTH and cortisol in swine.
- Antagonist experiments supported a GHRP-like receptor mechanism for Ipamorelin.
The available studies do not establish:
- a synergistic effect from combining GHRP-6 and Ipamorelin
- that combined exposure produces a greater GH response than either compound alone
- a combination-specific endocrine profile
- that separate experimental findings predict the behavior of a specific commercial blend
- therapeutic effects from the combination
The distinction between individual and combined treatment is important throughout this literature. The studies involving GHRP-6 and Ipamorelin evaluated the compounds separately, while the published combination studies identified above involved GHRH as the second component.
The Remaining Research Question
The existing studies establish that GHRP-6 and Ipamorelin can produce GH responses and that their broader endocrine profiles differ under the tested conditions.
The narrower research question is what happens when both compounds are evaluated together under controlled experimental conditions.
A combination study would need to compare GHRP-6, Ipamorelin and their combined exposure under the same experimental conditions and assess comparable endpoints. This would allow the combined response to be distinguished from the responses observed with each compound individually.
Until such evidence is available, the published research supports comparison of the individual experimental profiles, but does not establish a synergistic effect from the GHRP-6 and Ipamorelin combination.
Explore the GHRP-6 and Ipamorelin Stack at Direct SARMs to review its research-use specifications and available scientific information.
View research materialsFAQs
References
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. PubMed ↗
- Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. PubMed ↗
- Cordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993 Apr;76(4):819-23. PubMed ↗
